* A study comparing 22 patients with DUSP22-R ALCL to 59 patients without (DUSP22-NR) found that those with DUSP22-R were generally younger and had different expression profiles of certain markers (like CD15 and CD8), but their overall survival rates were similar to DUSP22-NR and lower than those with ALK-positive ALCL.
* Despite expectations, the research indicates that DUSP22-R ALCL does